TY - JOUR
T1 - Pattern of depressive symptoms in Parkinson's disease
AU - Farabaugh, Amy H.
AU - Locascio, Joseph J.
AU - Yap, Liang
AU - Weintraub, Daniel
AU - McDonald, William M.
AU - Agoston, Monica
AU - Alpert, Jonathan E.
AU - Growdon, John
AU - Fava, Maurizio
N1 - Funding Information:
Daniel Weintraub, M.D., has research support from Forest Pharmaceutical Laboratories, Inc. , the Office of Veterans Affairs , Boehringer Ingelheim , the National Institutes of Health , and the University of Pennsylvania . He is an educational consultant for AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Squib, Eisai Inc., GlaxoSmithKline, Teva Pharmaceutical Industries, Novartis Pharmaceuticals Corporation, Schwarz Pharma, Avanir Pharmaceuticals, and Boehringer Ingelheim.
Funding Information:
William M. McDonald, M.D., has research support from the Fuqua Foundation, the National Institute of Mental Health , the National Institute of Neurological Disease and Stroke , NeuroNetics, and Janssen Pharmaceutica . He is a consultant for NeuroNetics, Janssen Pharmaceutica, Forest Pharmaceuticals, Inc., and Bristol-Myers Squibb, and on the speakers’ bureau of Janssen Pharmaceutica, Forest Pharmaceuticals, Inc., Bristol-Myers Squibb, and Solvay Pharmaceuticals, Inc. Dr. McDonald has equity holdings in Amgen, Teva, Pfizer Inc., U.S. Pharmaceuticals Group, and Abbott Laboratories.
PY - 2009
Y1 - 2009
N2 - Background: Depressive symptoms are common in Parkinson's disease (PD); however, it is unclear whether there are specific depressive symptom patterns in patients with PD and comorbid depression (dPD). Objective: The goal of this study is to examine the frequency and correlates of specific depressive symptoms in PD. Method: A sample of 158 individuals with PD completed the self-rated Harvard Department of Psychiatry/National Depression Screening Day Scale (HANDS). By multiple-regression analysis, the authors examined the association between HANDS total and subscale scores and various demographic variables. Results: The frequency of depression was 37% (N=58). Patients with a history of depression before PD had significantly more serious depression than those who had no such history. Of those who were more depressed, the most common symptoms of depression endorsed were low energy, difficulty with concentration/making decisions, feeling blue, feeling hopeless, and having poor sleep. Conclusion: There is a relatively high prevalence of dPD. Items on the HANDS that discriminated best between depressed and nondepressed subjects with PD included feeling blue, feeling hopeless, feeling worthless, lack of interest, and self-blame. It remains to be defined whether dPD should be understood primarily as a psychological reaction to a physical disability or perceived impending one, or as a direct expression of the neuropathology of PD.
AB - Background: Depressive symptoms are common in Parkinson's disease (PD); however, it is unclear whether there are specific depressive symptom patterns in patients with PD and comorbid depression (dPD). Objective: The goal of this study is to examine the frequency and correlates of specific depressive symptoms in PD. Method: A sample of 158 individuals with PD completed the self-rated Harvard Department of Psychiatry/National Depression Screening Day Scale (HANDS). By multiple-regression analysis, the authors examined the association between HANDS total and subscale scores and various demographic variables. Results: The frequency of depression was 37% (N=58). Patients with a history of depression before PD had significantly more serious depression than those who had no such history. Of those who were more depressed, the most common symptoms of depression endorsed were low energy, difficulty with concentration/making decisions, feeling blue, feeling hopeless, and having poor sleep. Conclusion: There is a relatively high prevalence of dPD. Items on the HANDS that discriminated best between depressed and nondepressed subjects with PD included feeling blue, feeling hopeless, feeling worthless, lack of interest, and self-blame. It remains to be defined whether dPD should be understood primarily as a psychological reaction to a physical disability or perceived impending one, or as a direct expression of the neuropathology of PD.
UR - http://www.scopus.com/inward/record.url?scp=73249147087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73249147087&partnerID=8YFLogxK
U2 - 10.1176/appi.psy.50.5.448
DO - 10.1176/appi.psy.50.5.448
M3 - Article
C2 - 19855029
AN - SCOPUS:73249147087
SN - 0033-3182
VL - 50
SP - 448
EP - 454
JO - Psychosomatics
JF - Psychosomatics
IS - 5
ER -